| Literature DB >> 35986181 |
Joel J Credle1, Jonathan Gunn1, Puwanat Sangkhapreecha1, Daniel R Monaco1, Xuwen Alice Zheng1, Hung-Ji Tsai2, Azaan Wilbon1, William R Morgenlander1, Andre Rastegar1, Yi Dong3, Sahana Jayaraman1, Lorenzo Tosi4, Biju Parekkadan4, Alan N Baer5, Mario Roederer6, Evan M Bloch7, Aaron A R Tobian7, Israel Zyskind8,9, Jonathan I Silverberg10, Avi Z Rosenberg11, Andrea L Cox12, Tom Lloyd13,14, Andrew L Mammen13,15,16, H Benjamin Larman17.
Abstract
Pathogenic autoreactive antibodies that may be associated with life-threatening coronavirus disease 2019 (COVID-19) remain to be identified. Here, we show that self-assembled genome-scale libraries of full-length proteins covalently coupled to unique DNA barcodes for analysis by sequencing can be used for the unbiased identification of autoreactive antibodies in plasma samples. By screening 11,076 DNA-barcoded proteins expressed from a sequence-verified human ORFeome library, the method, which we named MIPSA (for Molecular Indexing of Proteins by Self-Assembly), allowed us to detect circulating neutralizing type-I and type-III interferon (IFN) autoantibodies in five plasma samples from 55 patients with life-threatening COVID-19. In addition to identifying neutralizing type-I IFN-α and IFN-ω autoantibodies and other previously known autoreactive antibodies in patient plasma, MIPSA enabled the detection of as yet unidentified neutralizing type-III anti-IFN-λ3 autoantibodies that were not seen in healthy plasma samples or in convalescent plasma from ten non-hospitalized individuals with COVID-19. The low cost and simple workflow of MIPSA will facilitate unbiased high-throughput analyses of protein-antibody, protein-protein and protein-small-molecule interactions.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35986181 DOI: 10.1038/s41551-022-00925-y
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 29.234